
    
      This is an single-center, open-label, dose-escalating study to evaluate the safety,
      pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple
      subcutaneous injection TK006 in patients with breast cancer-related bone metastases. It
      contains 4 cohorts：60 mg single-dose conhort, 120 mg single-dose conhort, 180 mg single-dose
      conhort and 120 mg Q4W （one dose every 4 weeks, 3 dose totally） conhort.
    
  